Fig. 2
Patients who were able to receive therapy subsequent to nivolumab showed significantly better overall survival than those who were not (p < 0.0001)
Fig. 2 | BMC Cancer
Patients who were able to receive therapy subsequent to nivolumab showed significantly better overall survival than those who were not (p < 0.0001)